Nutrition Department, Peter MacCallum Cancer Centre, East Melbourne, Australia.
Department of Haematology, Peter MacCallum Cancer Centre, East Melbourne, Australia. ; University of Melbourne, East Melbourne, Australia.
Curr Oncol. 2014 Apr;21(2):e334-9. doi: 10.3747/co.21.1820.
Patients undergoing myeloablative conditioning regimens and autologous stem-cell transplantation (asct) are at high risk of malnutrition. This randomized study aimed to determine if early nutrition support (commenced when oral intake is less than 80% of estimated requirements) compared with usual care (commenced when oral intake is less than 50% of estimated requirements) reduces weight loss in well-nourished patients undergoing high-nutritional-risk conditioning chemotherapy and asct. In the 50 well-nourished patients who were randomized, the outcomes evaluated included changes in weight and lean body mass (mid-upper arm circumference), length of stay, time to hemopoietic engraftment, and quality of life (Memorial Symptom Assessment Scale - Short Form). On secondary analysis, after exclusion of a single extreme outlier, both groups demonstrated significant weight loss over time (p = 0.0005). Weight loss was less in the early nutrition support group at time of discharge (mean: -0.4% ± 2.9% vs. -3.4% ± 2.6% in the usual care group, p = 0.001). This difference in weight was no longer observed at 6 months after discharge (mean: -1.0% ± 6.8% vs. 1.4% ± 6.1%, p = 0.29). In practice, an early start to nutrition support proved difficult because of patient resistance and physician preference, with 8 patients (33%) in the control group and 4 (15%) in the intervention group not commencing nutrition support when stipulated by the study protocol. No significant differences between the groups were found for other outcomes. In well-nourished patients receiving asct, early nutrition support maintained weight during admission, but did not affect other outcomes. Interpretation of results should take into consideration the difficulties encountered with intervention implementation.
接受清髓性预处理方案和自体干细胞移植(ASCT)的患者存在发生营养不良的高风险。本项随机研究旨在确定与常规治疗(当口服摄入量低于预计需求量的 50%时开始)相比,早期营养支持(当口服摄入量低于预计需求量的 80%时开始)是否可以减少接受高营养风险预处理化疗和 ASCT 的营养良好患者的体重减轻。在随机分组的 50 名营养良好的患者中,评估的结局包括体重和去脂体重(中上臂周径)的变化、住院时间、造血植入的时间以及生活质量(Memorial Symptom Assessment Scale-Short Form)。在二次分析中,排除单个极端异常值后,两组均显示随时间推移出现明显的体重减轻(p = 0.0005)。在出院时,早期营养支持组的体重减轻较少(平均值:-0.4% ± 2.9% vs. 常规治疗组-3.4% ± 2.6%,p = 0.001)。出院后 6 个月时,这种体重差异不再观察到(平均值:-1.0% ± 6.8% vs. 1.4% ± 6.1%,p = 0.29)。实际上,由于患者的抵抗力和医生的偏好,早期开始营养支持证明很困难,对照组的 8 名患者(33%)和干预组的 4 名患者(15%)未按照研究方案开始营养支持。两组之间的其他结局没有发现显著差异。在接受 ASCT 的营养良好的患者中,早期营养支持在住院期间维持体重,但对其他结局没有影响。解释结果时应考虑到干预实施所遇到的困难。